Non-Hodgkin's Lymphoma Clinical Trials

A listing of Non-Hodgkin's Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 123 clinical trials
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

acalabrutinib
rituximab
cyclin d1
bendamustine
  • 1270 views
  • 23 Jun, 2021
  • 250 locations
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

lymphoid leukemia
chronic lymphocytic leukemia
lymphoma
leukemia
hodgkin's disease
  • 5 views
  • 12 Jun, 2021
  • 11 locations
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to determine the recommended Phase 2 dose regimen or the maximum tolerated dose of JNJ-67856633 in participants with relapsed/ refractory B-cell non-Hodgkin lymphoma

beta human chorionic gonadotrophin
chronic lymphocytic leukemia
b-cell lymphoma
lymphoid leukemia
lymphoma
  • 81 views
  • 23 Jun, 2021
  • 47 locations
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the RP2D(s) in Part B.

tyrosine
large b-cell lymphoma
measurable disease
mantle cell lymphoma
leukemia
  • 0 views
  • 24 Jun, 2021
  • 33 locations
A Safety and Preliminary Efficacy Study of CC-99282 Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL)

CC-99282-NHL-001 study is a Phase I dose escalation and expansion clinical study of CC-99282 administered alone and in combination with rituximab in subjects with relapsed or refractory non

neutrophil count
hodgkin's disease
rituximab
blood transfusion
  • 33 views
  • 22 Jun, 2021
  • 32 locations
Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

The purpose of the study is to assess the efficacy and safety of tisagenlecleucel in children and adolescents with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). For pediatric

large b-cell lymphoma
gilbert's syndrome
measurable disease
burkitt's lymphoma
leukemia
  • 6 views
  • 14 Jun, 2021
  • 36 locations
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.

large b-cell lymphoma
anthracyclines
carbon monoxide
apheresis
neutrophil count
  • 48 views
  • 19 Jun, 2021
  • 74 locations
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma

This open-label Phase 2 study will evaluate the safety and efficacy of modified T cells (JCAR017) administered to adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The study will

rituximab
anthracyclines
b-cell lymphoma
high dose chemotherapy
diffuse large b-cell lymphoma
  • 191 views
  • 25 Jun, 2021
  • 29 locations
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.

  • 40 views
  • 23 Jun, 2021
  • 119 locations
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

This is a Phase 3 study of the PI3K inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.

rituximab
measurable disease
prednisone
chop regimen
bendamustine
  • 0 views
  • 13 Jun, 2021
  • 3 locations